ProPhase Labs, Inc. Income Taxes Paid
ProPhase Labs, Inc. (PRPH) reported Income Taxes Paid of $12.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-19
- ProPhase Labs, Inc. income taxes paid, net for the quarter ending 2025-12-31 was $551.00K, a 107.14% increase year-over-year.
- ProPhase Labs, Inc. income taxes paid, net for the quarter ending 2025-09-30 was $747.00K, a 83.99% increase year-over-year.
- ProPhase Labs, Inc. income taxes paid, net for the quarter ending 2025-06-30 was $91.00K, a 33.09% decline year-over-year.
- ProPhase Labs, Inc. income taxes paid, net for the quarter ending 2025-03-31 was $256.00K, a 19.50% decline year-over-year.
- ProPhase Labs, Inc. income taxes paid, net for fiscal 2025 was $1.65M, a 46.09% increase from fiscal 2024.
- ProPhase Labs, Inc. income taxes paid, net for fiscal 2024 was $1.13M, a 62.47% decline from fiscal 2023.
- ProPhase Labs, Inc. income taxes paid, net for fiscal 2023 was $3.00M, a 76.89% increase from fiscal 2022.
- ProPhase Labs, Inc. income taxes paid, net for fiscal 2022 was $1.70M.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 3 month as first filed | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 6 month as first filed | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 9 month as first filed | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.00K 10-Q · filed 2026-08-19 | ||||||
| 2025-12-31 | $551.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.30M derived: sum of 2 quarters · filed 2026-06-01 | $1.39M derived: sum of 3 quarters · filed 2026-08-19 | $1.65M 10-K · filed 2026-06-01 | |||
| 2025-09-30 | $747.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $838.00K derived: sum of 2 quarters · filed 2026-08-19 | $1.09M 10-Q · filed 2025-11-19 | $1.36M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-06-30 | $91.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $347.00K 10-Q · filed 2026-08-19 | $613.00K derived: sum of 3 quarters · filed 2026-08-19 | $1.02M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-03-31 | $256.00K 10-Q/A · filed 2026-07-09 | $522.00K derived: sum of 2 quarters · filed 2026-07-09 | $928.00K derived: sum of 3 quarters · filed 2026-07-09 | $1.06M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2024-12-31 | $266.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $672.00K derived: sum of 2 quarters · filed 2026-06-01 | $808.00K derived: sum of 3 quarters · filed 2026-06-01 | $1.13M 10-K · filed 2026-06-01 | |||
| 2024-09-30 | $406.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $542.00K derived: sum of 2 quarters · filed 2025-11-19 | $860.00K 10-Q · filed 2025-11-19 | $860.00K derived: sum of 4 quarters · filed 2025-11-19 | |||
| 2024-06-30 | $136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $454.00K 10-Q · filed 2025-08-13 | $454.00K derived: sum of 3 quarters · filed 2025-08-13 | $454.00K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $318.00K 10-Q · filed 2025-05-20 | $318.00K derived: sum of 2 quarters · filed 2025-05-20 | $318.00K derived: sum of 3 quarters · filed 2025-05-20 | $1.82M derived: sum of 4 quarters · filed 2025-05-20 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 derived: sum of 2 quarters · filed 2025-04-01 | $1.50M derived: sum of 3 quarters · filed 2025-04-01 | $3.00M 10-K · filed 2025-04-01 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.50M derived: sum of 2 quarters · filed 2024-11-13 | $3.00M 10-Q · filed 2024-11-13 | $3.20M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $3.00M 10-Q · filed 2024-08-14 | -$3.00M 10-Q · filed 2023-08-11 | $3.20M derived: sum of 3 quarters · filed 2024-08-14 | $6.20M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-10 | -$1.50M 10-Q · filed 2023-05-12 | $1.70M derived: sum of 2 quarters · filed 2024-05-10 | $4.70M derived: sum of 3 quarters · filed 2024-05-10 | $3.20M derived: sum of 4 quarters · filed 2024-05-10 | ||
| 2022-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $3.20M derived: sum of 2 quarters · filed 2024-03-29 | $1.70M derived: sum of 3 quarters · filed 2024-03-29 | $1.70M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.50M derived: sum of 2 quarters · filed 2023-11-13 | $1.50M 10-Q · filed 2023-11-13 | -$1.50M 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$1.50M 10-Q · filed 2023-08-11 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-12 | ||||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-29 | ||||||
| 2019-12-31 | $103.00K 10-K · filed 2021-03-31 | ||||||
| 2018-12-31 | $738.00K 10-K · filed 2019-03-26 | ||||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $0.00 derived: sum of 2 quarters · filed 2019-03-26 | $1.35M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $1.35M 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $1.35M 10-Q · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |